Aminoguanidine holds back the
signs of aging

Aminoguanidine inhibits the ‘cross-linking’ (or glycosylation) of proteins which may cause many of the problems of old age

It is believed that the cross-linking of the proteins that make up the human body play a role in the human aging process. Cross-linking is the process that causes food to turn yellow and become tough with age. Similarly with humans, cross-linking may be responsible for many of the problems of old age, including senile cataracts, thickening of the arteries, some cancers and damage to the immune system.

A weakened immune system increases the body’s susceptibility to infection. An increased likelihood of some cancers can also occur due to the effects of glucose on DNA. DNA contains all the information necessary to create a normal cell, however it can react with glucose to produce damaged DNA, which in turn causes abnormal cells to be produced.

One study conducted on animals showed that Aminoguanidine prevented age-related enlargement of the heart. The membrane surface area was reduced by 30%. Furthermore, the collagen content of their arterial walls was increased by 24-30%.

Studies conducted at the University of Milan over the last 25 years have shown Aminoguanidine’s ability to reduce the ability of very low density lipoprotein (‘bad cholesterol’) to bind itself to blood vessel walls. In turn, blood platelets are less likely to coagulate and form dangerous clots.

In addition, Aminoguanidine has an ability to treat patients whose blood vessels are constricted by arteriosclerosis. In 1992 at the University of Milan, 11 patients with peripheral vascular disease were treated with Aminoguanidine. Their blood vessels were so clogged that they couldn’t walk for more than 500 yards, but after treatment the patients blood flow improved on average by 30% and the patients exercise abilities improved by 50% to 105%.

Most interestingly of all, Aminoguanidine may have the potential to slow the aging process by protecting the proteins that make up the human body. These include the skin proteins (collagen and elastin), eye lens protein, nerve protein and kidney proteins. All these vital proteins deteriorate with advancing age, even more so in diabetics who have 2-3 times the number of cross-linked proteins than non-diabetics. The result of this being that Aminoguanidine may be able to protect us from (or slow down the progression of) age-related toughening and yellowing of the skin as well as cataract conditions.

Diabetes is often seen as a form of accelerated aging and research into diabetes has provided support for the idea that cross-linking causes aging. A number of different studies with diabetic rats indicate that Aminoguanidine administered rats have significantly superior survival rates than those who are untreated. Diabetic clinical trials with humans have also highlighted Aminoguanidine’s ability to prevent oxidative modification of low-density lipoproteins (LDL) and inhibit the formation of atherosclerotic plaques.

Not surprisingly, therefore, Aminoguanidine is an exciting new weapon in the armoury of anti-aging medicine.

Dosage:
Take 75mg two, three of four times a day. Aminoguanidine has a half-life of approximately 4-hours, therefore it is preferable to spread the dosage over the day.

Side effects:
Possible nausea and headache. But as human clinical trials are still relatively limited, dosages shouldn't be exceeded unless under the supervision of a physician.

Caution:
Aminoguanidine can inhibit the uptake of vitamin B6, so a B6 supplement is recommended whilst using Aminoguanidine. Aminoguanidine may be synergistic with Acarbose and Metformin.

Please note:
We supply a hydrochloride (HCL) based tablet. This is more expensive than a bicarbonate based version, but the HCL is more soluble, less irritating and is the type used in the clinical trials.

Update:
Our new formulation of Aminoguanidine now contains 10mg of B6 in each tablet so you no longer have to remember to supplement with this vitamin!

What our customers say...

Aminoguanidine is one of the new drugs in a unique class called Advanced Glycation End product inhibitors which abbreviates to AGE-inhibitor. From the information that is coming to light in clinical trials, these novel drugs may prove to be just that- age inhibitors! Phil Micans PharmB, Great Britain. I've been waiting to try this new anti-aging product for some time, congratulations on making it available. D.C., New York. I believe that whilst these anti protein cross-linking substances have benefit in many disorders that their true benefits will be in preventative medicine. S.D., Malta.